Despite advances in the treatment of cancer, recurrence and metastasis continue to pose major problems in clinical management. The relationship between circulating tumour cells and the development of secondary disease is not fully understood. However, a method to detect small numbers of such cells may provide a tool with which to evaluate their role in the disease process, and by implication the possible benefits of eliminating them. One area of convergence between molecular biology and clinical cancer medicine has been in the new methods for detecting systemic spread of tumour cells.
Morphology, flow cytometry and conventional cytogenetics have been used to detect circulating tumour cells at a level of 1 in 100, and the more sensitive method of immunocytochemistry may detect one tumour cell in 105 normals (Molino et al., 1991; Osborne et al., 1991) . This technique is, however, dependent upon the availability of antibodies to tumour-associated cell-surface antigens and may be subject to false positives when antibodies cross-react or tumour antigens are presented on host immune cells (Heydermann and McCartney, 1985) .
The advent of the polymerase chain reaction (PCR) and the ability to amplify a specific region of DNA between defined oligonucleotide sequences using repeated cycles of denaturation, annealing and extension has made an enormous impact upon nucleic acid analysis (Saiki et al., 1986) . By amplification of tumour-specific sequences, the PCR has been shown in a variety of studies to detect one malignant cell in up to 107 normal cells (Mattano et al., 1992; Alkan et el., 1993; Cross et al., 1993; Fabrega et al., 1993; Datta et al., 1994; Gerhard et al., 1994; Negrin and Pesando, 1994) . This increases the sensitivity of detection by an order of magnitude when compared with immunocytochemistry.
Studies of PCR amplification of tumour-specific DNA sequences have been possible mainly in haematological malignancies in which consistent and well-characterised molecular abnormalities are present. For solid tumours such abnormalities are uncommon and other strategies are required. We and others have used the amplification of tissue-specific RNA, after reverse transcription, as a marker of solid tumour cells in the blood, thus avoiding the requirement for a DNA sequence abnormality (Smith et al., 1991; Burchill et al., 1994a) .
Methods
The choice of target for amplification is evidently determined by the specific characteristics of the malignant cells. Genomic (Fukuhara et al., 1992; Cross et al., 1993; Meijerink et al., 1993) or the use of serial dilutions (Brisco et al., 1994 (Potter et al., 1992; Nizet et al., 1993 (Dreyfuss et al., 1993; Bird et al., 1994) . The rational development of in vitro treatments for these harvests by methods such as CD34+ cell selection or immunomagnetic 'purging' will depend upon these analyses for proof of efficacy.
The study of PCR for immunoglobulin and T-cell receptor gene rearrangements has been successfully applied to lymphoblastic leukaemia (ALL) (Yamada et al., 1990) . Several groups have demonstrated that the approach is feasible, with up to 90% of childhood ALL patients having amplifiable clonal markers (Steward et al., 1994) . In one study of 152 patients, those with a monoclonal band still detectable following induction therapy showed a 57% recurrence rate as compared with 25% for those in whom only polyclonal products were seen. (Brisco et al., 1993) . Other smaller studies have confirmed the relationship between recurrence rate and PCR positivity (Neale et al., 1991; Nizet et al., 1993) , a relationship which appears to hold for quantitative estimations of the number of residual leukaemic blasts (Brisco et al., 1994) . The rate of decline of clonal cell numbers during treatment has also been shown to correlate with the probability of recurrence in some small studies (Nizet et al., 1993; Cave et al., 1994) . Unfortunately, there is also a low but definite recurrence rate even for those in whom no clonal population can be identified, possibly owing to clonal evolution (Langlands et al., 1993; Steward et al., 1994 (Limpens et al., 1991; Aster et al., 1992) and even normal blood donors (Limpens et al., 1992) , while the lymphoma-associated clone may be detected in the blood of patients in remission for several years aher both conventional (Price et al., 1991a; Finke et al., 1993) and myeloablative therapy (Johnson et al., 1994) . There are certainly some data to suggest that failure to remove t(14;18)-bearing cells from autologous bone marrow harvests is associated with earlier recurrence following their use for haemopoietic rescue (Gribben et al., 1991) , although this has not been confirmed in other studies (Johnson et al., 1994) . Despite the uncertainty regarding the presence of translocation-bearing cells in prolonged remission, the intuitive suggestion that patients are more likely to remain disease free if the clone is eliminated seems to be supported by some data. Patients with PCR-positive bone marrow during followup after myeloablative treatment have earlier recurrences (Gribben et al., 1993) , although the relationship is less clear in peripheral blood (Gribben et al., 1994) . New immunotherapeutic strategies are now being implemented to treat such patients on the basis of PCR results (Grossbard et al., 1993) .
A variety of other chromosomal rearrangements which have been described in lymphoma are detectable by PCR. All require mRNA and a reverse transcription step. The translocations described and the genes involved are shown in Table I . The t(8;14), t(2;5) and t(3;14) are all amenable to this approach, although the t(11;14)(ql3;q32) of centrocytic lymphoma shows a scattering of breakpoints on chromosome 11 which makes the use of one set of primers inadequate. No studies have yet been carried out using these rearrangements as markers of disease although they have found some use in diagnosis.
The Philadelphia chromosome One of the earliest transfers from classical cytogenetics to molecular biology was the identification of the BCR and ABL genes on either side of the t(9;22)(q34;ql 1) in chronic myeloid leukaemia (CML) and some cases of ALL. This translocation is now detectable by RT-PCR using different sets of primers for the p190 and p210 variants (Kawasaki et al., 1988) . The PCR has been used for monitoring patients with CML following treatment, in particular myeloablative therapy and allogeneic bone marrow transplantation (Gabert et al., 1989; Morgan et al., 1989; Roth et al., 1989; Sawyers et al., 1990 (Carella et al., 1993) . Similarly, in vitro culture of bone marrow may result in selection of t(9;22)-negative stem cells (Udomsakdi et al., 1992; Fabrega et al., 1993) . Tumour cell contamination is a critical factor in both these approaches, and RT-PCR has been used for rapid determination of the quality of reinfused progenitors (Allieri et al., 1992; Nagafuji et al., 1993) .
Retinoic acid receptor gene translocations The characteristic translocation of acute promyelocytic leukaemia (APML) is the t(15;17)(q22;ql 1), which transposes the retinoic acid receptor a and PML genes (de The et al., 1990) . These have been cloned and RT-PCR used to define at least three isoforms, which have been used to monitor residual disease at the end of therapy (Biondi et al., 1992; Castaigne et al., 1992; Miller et al., 1992) . The presence of different isoforms complicates the PCR, requiring several sets of primers in order to cover the different breakpoints involved (Chang et al., 1992; Chen et al., 1992; Matsuoka et al., 1993) . There has been some suggestion that patients with translocations in exon 3 of PML have a worse prognosis than those with intron 6 breakpoints, but this is based upon a small number of observations in patients treated with an unusual type of chemotherapy (Huang et al., 1993 really does persist in patients with durable remissions. As in lymphoma, several consistent chromosomal rearrangements have been characterised at the molecular level in acute leukaemias of various types, all of which may in future be used for the detection of residual disease by RT-PCR. These are shown in Table 1I .
Solid tumours
The cytogenetics of solid tumours are considerably more complex and less well defined than those of haematological malignancy, hence there have been few opportunities to apply PCR techniques to aid diagnosis or monitor disease following treatment (Table III) .
The best-characterised abnormalities in solid tumours Prostate-specific antigen (PSA) mRNA was identified in the peripheral blood (Moreno et al., 1992) and lymph nodes (Deguchi et al., 1993) of small numbers of patients with prostate cancer but not in controls, with a level of sensitivity that appeared better than immunocytochemistry. Further refinement and increased sensitivity have been reported using the recently cloned prostate-specific membrane (PSM) antigen as a target (Israeli et al., 1994) . The rate of detection using nested RT-PCR for PSM appeared to be markedly superior following radical prostatectomy, with 68% of patients with negative PSA serology having positive PSM results by PCR as compared with 3% for PSA. In view of difficulties of interpretation for slightly raised levels of PSA and the long natural history of asymptomatic prostate cancer, it is difficult to know whether an increase in sensitivity is likely to contribute usefully to management. The use of such a marker following prostatectomy might be predictive of recurrence, and it will be interesting to see whether trials of hormonal therapy will confer benefit in this setting.
Carcinoembryonic antigen (CEA) expression has been investigated as a marker of gastrointestinal and breast cancer. RT-PCR for CEA was used to detect tumour cells in the bone marrow of 14 of 21 patients, with dilution experiments suggesting a level of sensitivity of 2-5 tumour cells in 107 normal cells (Gerhard et al., 1994) . In 56 normal control marrow samples no CEA expression was found, indicating that other members of the CEA gene family expressed on myeloid cells did not interfere. The sensitivity of tumour cell detection by RT-PCR was greater than by immunocytology for CEA or cytokeratins.
In neuroblastoma two different targets for RT-PCR have been analysed. Expression of PGP-9.5, a protein related to neurone-specific enolase (NSE), has been reported as a useful marker (Mattano et al., 1992 ). The original report described low levels of expression in normal peripheral blood and bone marrow which did not appear to interfere with tumour cell detection. However, a more recent study found levels of PGP-9.5 expression in normal haemopoietic tissue sufficient to exclude its usefulness as a marker (Norris et al., 1994) . Expression of tyrosine hydroxylase, the first enzyme in the catecholamine synthesis pathway, has been used to detect neuroblastoma cells in three separate studies. These have shown tyrosine hydroxylase to be the target of choice for examinations of bone marrow (Naito et al., 1991), peripheral blood and peripheral blood progenitor cells (Burchill et al., 1994a) ; Norris et al., 1994) . Dilution experiments have demonstrated detection of one tumour cell in 105 normal marrow cells (Naito et al., 1991) or 1 in IO' normal blood cells (Burchill et al., 1994a) . No transcription of tyrosine hydroxylase has been found in normal haemopoietic tissue. Studies of blood samples from 23 patients showed some correlation with clinical outcome: 13 of 23 presentation samples were Gerhard, et al. (1994) Neuroblastoma PGP-9.5b Mattano et al. (1992) (Nagle, 1988 
